Experienced in Stroke

Dr. Paul G. Matherne

Family Medicine
1924 E Pass Rd, 
Gulfport, MS 
Accepting New Patients
Offers Telehealth
Experienced in Stroke
1924 E Pass Rd, 
Gulfport, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Matherne is a primary care provider, practicing in Family Medicine in Gulfport, Mississippi. Dr. Matherne is rated as an Experienced provider by MediFind in the treatment of Stroke. His top areas of expertise are Glucocorticoid-Remediable Aldosteronism, Hypertension, Familial Hypertension, Maturity Onset Diabetes of the Young, and Gastrostomy. Dr. Matherne is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in MS
Hospital Affiliations
Singing River Health System
Merit Health Biloxi
Singing River Gulfport
Memorial Hospital At Gulfport
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

1924 E Pass Rd, Gulfport, MS 39507

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
Enrollment Status: Completed
Publish Date: December 13, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection
Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
Enrollment Status: Completed
Publish Date: August 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

2 Total Publications

Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
Journal: The Lancet. Infectious diseases
Published: March 22, 2024
Similar Doctors
Distinguished in Stroke
Dr. Vishwanth R. Mallipeddi
Family Medicine
Distinguished in Stroke
Dr. Vishwanth R. Mallipeddi
Family Medicine

Imc-Hospitalists LLC

5 Mobile Infirmary Cir, 
Mobile, AL 
 (59.2 miles away)
251-435-7289
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vishwanth Mallipeddi is a primary care provider, practicing in Family Medicine in Mobile, Alabama. Dr. Mallipeddi is rated as an Advanced provider by MediFind in the treatment of Stroke. His top areas of expertise are Stroke, COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), Colonoscopy, and Endoscopy. Dr. Mallipeddi is currently accepting new patients.

Advanced in Stroke
Dr. Timothy M. Iliff
Family Medicine | Internal Medicine
Advanced in Stroke
Dr. Timothy M. Iliff
Family Medicine | Internal Medicine

Alabama Post-Acute Medical Service 1 PC

735 S Washington Ave, 
Mobile, AL 
 (60.3 miles away)
251-433-2642
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Iliff is a primary care provider, practicing in Family Medicine and Internal Medicine in Mobile, Alabama. Dr. Iliff is rated as an Advanced provider by MediFind in the treatment of Stroke. His top areas of expertise are Dementia, Subacute Cerebellar Degeneration, Alzheimer's Disease, and End-Stage Renal Disease (ESRD). Dr. Iliff is currently accepting new patients.

Experienced in Stroke
Dr. Rick D. Hoover
Family Medicine
Experienced in Stroke
Dr. Rick D. Hoover
Family Medicine
8735 Hwy 613, 
Moss Point, MS 
 (32.8 miles away)
228-219-3684
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rick Hoover is a primary care provider, practicing in Family Medicine in Moss Point, Mississippi. Dr. Hoover is rated as an Advanced provider by MediFind in the treatment of Stroke. His top areas of expertise are End-Stage Renal Disease (ESRD), Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Dementia. Dr. Hoover is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matherne's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 72 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile